Total API product pipeline of 237 filings across regions: Jubliant Life Sciences

Products and services of the Company reach out to clients in 98 countries of the world. International revenues contribute 74% of the revenue mix at Rs. 999 crore, up 10% YoY, with the share of key developed markets revenue standing at Rs.796 crore, contributing


Jubliant Life Sciences Ltd, an integrated pharmaceutical and life science company approved Financial results for the quarter ended June, 2013.

Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said,"We are witnessing a strong underlying momentum in the life science ingredients space, where volume growth has maintained course.

On the other hand the pharmaceuticals segment is delivering with strong growth in APIs. Further they added " We expect strong operational performance in pharmaceuticals due to new product launches and geographic expansion and higher capacity utilisation in Nutrition ingredients and proprietary products with the uptrend in pricing."

Q1 FY14 Highlights:

- Revenue growth was driven by volume growth in both segments but prices remained under pressure for pharmaceutical business.

- Consolidated revenue up 9% YoY

- Interanational revenues at Rs. 999 crore, contributing 74% to the overall mix and up 10% YoY

- EBITDA margins at 17.5% and normalised PAT margins at 5.1%

- The company had total of 649 filings for formulations of which 189 have been approved in various regions of the world including 58 ANDAs in  the US and 41 Dossier filings in the Europe.

- Income from operations was at Rs. 706 crore better by 18% YoY and having 52% share in overall revenues.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email